The repurchase program continues on schedule with approximately DKK 3.4 billion remaining under the current tranche. Monitor for any changes in the pace of buybacks or completion of the program.
NVO drugs
NVO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $40.19entry
- T+1 · 13d ago +4.95%α +3.30% · $42.18
- T+5 · 7d ago +1.27%α +1.86% · $40.70
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novo Nordisk filed a routine 6-K updating its ongoing share repurchase program, reporting the repurchase of 1.44 million B shares for approximately DKK 377 million during the week ended November 2, 2026. The filing is a standard periodic update with no material new information about the company's financial performance or outlook.
Key Facts
- Novo Nordisk repurchased 1,440,000 B shares from October 26 to November 2, 2026, at an average price of DKK 261.85 per share, for a total transaction value of approximately DKK 377 million.
- Since the program's initiation on May 6, 2026, the company has repurchased 26,955,000 B shares for a total of DKK 7,764,364,812.
- The overall share repurchase program authorizes up to DKK 15 billion over a 12-month period beginning February 4, 2026; as of November 2, 2026, Novo Nordisk has repurchased 41,714,179 B shares at an average price of DKK 277.23 per share, totaling DKK 11,564,364,801.
- Novo Nordisk holds 55,754,876 B shares as treasury shares, representing 1.2% of the total share capital of 4,465,000,000 shares.
Financial Impact
No material financial impact; the filing reports routine share repurchase transactions under a previously announced program.
Risk Factors
- No new risks identified; this is a routine update on an ongoing capital return program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-007060 |
| Document: 0001171843-26-007060-index-headers.html | 0001171843-26-007060 |
| Document: 0001171843-26-007060-index.html | 0001171843-26-007060 |
| Document: 0001171843-26-007060.txt | 0001171843-26-007060 |
| Earnings Context (Synthetic; results releases only) | 0001171843-26-007060 |
Track record
43 reports on NVO
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +23.56% at T+60 after the Jul 28, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $41.89 Now $41.60 −0.69% settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 3/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 1/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
- Nov 9, 20267d ago 6-K Neutral 2/10 Entry $41.38 Now $41.60 +0.53% settles Dec 8
- Nov 5, 202611d ago Institutional Cluster Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
- Nov 5, 202611d ago 6-K Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
- Nov 4, 202612d ago 6-K Bullish 6/10 Entry $42.18 Now $41.60 −1.38% settles Dec 3
- Nov 3, 202613d ago 6-K Neutral 2/10 Viewing Entry $40.19 Now $41.60 +3.51% settles Dec 2
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $39.13 Now $41.60 +6.31% settles Nov 23
- Oct 26, 202622d ago Court Ruling Neutral 4/10 Entry $38.67 Now $41.60 +7.58% settles Nov 24
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers